Evidence map›Paper›PMID 39778552›Full record

ArticleOncology2025

Analysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma: A Single-Center Retrospective Study.

Tomoki Higashiyama, Kozo Kuribayashi, Hiroshi Doi, Aki Kubota, Taiichiro Otsuki, Yasuhiro Nakajima, Koji Mikami, Ryo Takahashi, Akifumi Nakamura, Daichi Fujimoto and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tomoki HigashiyamaDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Kozo KuribayashiDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Hiroshi DoiDepartment of Radiation Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
Aki KubotaDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Taiichiro OtsukiDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Yasuhiro NakajimaDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Koji MikamiDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Ryo TakahashiDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Akifumi NakamuraDivision of Thoracic Surgery, Department of Surgery, Hyogo Medical University, Nishinomiya, Japan.
Daichi FujimotoDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Kazuhiro KitajimaDepartment of Radiology, Hyogo Medical University, Nishinomiya, Japan.
Toshiyuki MinamiDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.
Takashi KijimaDepartment of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn August 2018, the Japanese PMDA approved nivolumab, an immune checkpoint inhibitor, for previously treated, unresectable, advanced, or recurrent pleural mesothelioma (PM) based on the MERIT trial, a phase II study of 34 cases. However, concerns regarding limited evidence persist.

methodsWe retrospectively analyzed 83 patients with previously treated, unresectable, advanced, or recurrent malignant PM treated with nivolumab from August 2018 to May 2022. Efficacy was evaluated using overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) per modified RECIST criteria. Safety was assessed by treatment-related adverse events (TRAEs) according to CTCAE v5.0. PD-L1 expression was analyzed with the anti-PD-1 antibody (22C3).

resultsThe median age was 73 years. Histological subtypes included epithelioid (60), sarcomatoid (15), biphasic (6), and unknown (2). Lines of treatment were 2nd (62), 3rd (13), and 4th or later (8). Partial response was seen in 16 patients, stable disease in 30, progressive disease in 29, and not evaluable in 8, with an ORR of 19.3% and a disease control rate of 55.4%. Median PFS and OS were 5.1 and 12.4 months, respectively. TRAEs occurred in 45 patients (54.2%), with grade ≥3 in 6 (7.2%) and one treatment-related death. PFS correlated with male gender, TRAEs, and good performance status (PS: 0-1), while OS correlated with PS.

conclusionNivolumab demonstrated efficacy and safety in clinical practice, supporting its use in patients with good PS, even in later lines.

Indexed as

Antineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsMesotheliomaMesothelioma, MalignantNeoplasm Recurrence, LocalNivolumabPleural NeoplasmsAgedAged, 80 and overB7-H1 AntigenFemaleHumansMaleMiddle AgedProgression-Free SurvivalRetrospective StudiesAntineoplastic Agents, ImmunologicalB7-H1 AntigenImmune Checkpoint InhibitorsNivolumabAnti-PD-1 AbImmune checkpoint inhibitorNivolumabPleiotropic effectPleural mesothelioma

Identifiers

PMID39778552
PMCPMC12401528

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.